



# Claims


1. A compound represented by formula (I), a salt of the compound, or a solvate of the compound or the salt:




wherein the group represented by formula (1):



is any of the groups represented by formula (a) to (c):



(wherein Ar<sub>1</sub> and Ar<sub>2</sub> each independently represent a 6-membered aromatic heterocyclic group which may have a substituent or a phenyl group which may have a substituent; and R<sup>2</sup> represents a group selected from among a hydrogen atom, a halogeno group, a hydroxyl group, a lower alkoxy group, and a lower alkyl group which may have a substituent); X represents a carbonyl group or a thiocarbonyl group; and Y represents a group represented by formula (2):



(wherein the ring structure A represents a 4- to 7-membered ring which may have, in addition to N shown in formula (2), one hetero atom selected from among N, O, and S; and the ring structure A may have a substituent represented by R<sup>1</sup>, wherein R<sup>1</sup> represents 1 to 4 groups, which are identical to or different from one another, selected from among a hydroxyl group, a cyano group, an oxo group, a halogeno group, a lower alkyl group which may have a substituent, a lower alkoxy group, an aralkyloxy group, a lower thioalkoxy group, a lower alkoxy carbonyl group, an aralkyloxy carbonyl group, a lower acyl group, a carboxyl group, a hydroxyiminocarbonyl group, an alkoxyimino group, a lower alkylsulfonyl group, an amino group which may have a substituent, a carbamoyl group which may be substituted by a lower alkyl group, an aminosulfonyl group which may be substituted by a lower alkyl group, a 3- to 6-membered spiro-alicyclic alkyl group which may have a substituent, and a 4- to 7-membered alicyclic heterocyclic group which may have a substituent).

2. A compound as described in claim 1, a salt of the compound, or a solvate of the compound or the salt, wherein the group represented by formula (1) is a group represented by formula (b), and R<sup>1</sup> in formula (2) represents 1 to 4 groups, which are identical to or different from one another, selected from among a cyano group, an oxo group, a halogeno

group, a lower alkyl group which has been substituted by a halogeno group, a lower alkoxy group, an aralkyloxy group, a lower thioalkoxy group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, a lower acyl group, a carboxyl group, a hydroxyiminocarbonyl group, an alkoxyimino group, a lower alkylsulfonyl group, an amino group which may have a substituent, a carbamoyl group which may be substituted by a lower alkyl group, an aminosulfonyl group which may be substituted by a lower alkyl group, a 3- to 6-membered spiro-alicyclic alkyl group which may have a substituent, and a 4- to 7-membered alicyclic heterocyclic group which may have a substituent.

3. A compound as described in claim 1 or 2, a salt of the compound, or a solvate of the compound or the salt, wherein X is a carbonyl group.

4. A compound as described in any one of claims 1 to 3, a salt of the compound, or a solvate of the compound or the salt, wherein Ar<sub>1</sub> in formula (I) is a pyridyl group which may have a substituent or a pyridazinyl group which may have a substituent.


5. A compound as described in any one of claims 1 to 3, a salt of the compound, or a solvate of the compound or the salt, wherein Ar<sub>1</sub> in formula (I) is a phenyl group which may have a substituent.

6. A compound as described in any one of claims 1 to 5, a salt of the compound, or a solvate of the compound or the salt, wherein Ar<sub>2</sub> in formula (I) is a pyridyl group which may

have a substituent.

7. A compound as described in any one of claims 1 to 5, a salt of the compound, or a solvate of the compound or the salt, wherein  $\text{Ar}_2$  in formula (I) is a phenyl group which may have a substituent.


8. A compound as described in any one of claims 1 to 7, a salt of the compound, or a solvate of the compound or the salt, wherein the group represented by formula (1) is a group represented by formula (a):



(a)

wherein  $\text{Ar}_1$  and  $\text{Ar}_2$  have the same meanings as described above.


9. A compound as described in any one of claims 1 to 7, a salt of the compound, or a solvate of the compound or the salt, wherein the group represented by formula (1) is a group represented by formula (b):



(b)

wherein  $\text{Ar}_1$ ,  $\text{Ar}_2$ , and  $\text{R}^2$  have the same meanings as described above.

10. A compound as described in any one of claims 1 to 7, a salt of the compound, or a solvate of the compound or the salt, wherein the group represented by formula (1) is a group represented by formula (c):



(c)

wherein Ar<sub>1</sub> and Ar<sub>2</sub> have the same meanings as described above.

11. A compound as described in any one of claims 1 to 10, a salt of the compound, or a solvate of the compound or the salt, wherein the ring structure A in formula (2) is a ring selected from among azetidine, pyrrolidine, piperidine, piperazine, morpholine, homopiperazine, and oxazepane, and R<sup>1</sup> represents 1 to 4 groups, which are identical to or different from one another, selected from among a hydroxyl group, a cyano group, an oxo group, a halogeno group, a lower alkyl group which may have a substituent, a lower alkoxy group, an aralkyloxy group, a lower thioalkoxy group, a lower alkoxycarbonyl group, an aralkyloxycarbonyl group, a lower acyl group, a carboxyl group, a hydroxyiminocarbonyl group, an alkoxyimino group, a lower alkylsulfonyl group, an amino group which may have a substituent, a carbamoyl group which may be substituted by a lower alkyl group, an aminosulfonyl group which may be substituted by a lower alkyl group, a 3- to 6-membered spiro-alicyclic alkyl group which may have a substituent, and a 4- to 7-membered alicyclic heterocyclic group which may have a substituent.

12. A compound as described in any one of claims 1 to 10, a salt of the compound, or a solvate of the compound or the salt, wherein the ring structure A in formula (2) is a ring selected from among azetidine, pyrrolidine, piperidine,

piperazine, morpholine, homopiperazine, and oxazepane, and  $R^1$  represents 1 to 4 groups, which are identical to or different from one another, selected from among a cyano group, an oxo group, a halogeno group, a lower alkyl group which has been substituted by a halogeno group, a lower alkoxy group, an aralkyloxy group, a lower thioalkoxy group, a lower alkoxy carbonyl group, an aralkyloxy carbonyl group, a lower acyl group, a carboxyl group, a hydroxyiminocarbonyl group, an alkoxyimino group, a lower alkylsulfonyl group, an amino group which may have a substituent, a carbamoyl group which may be substituted by a lower alkyl group, an aminosulfonyl group which may be substituted by a lower alkyl group, a 3- to 6-membered spiro-alicyclic alkyl group which may have a substituent, and a 4- to 7-membered alicyclic heterocyclic group which may have a substituent.

13. A compound as described in any one of claims 1 to 10, a salt of the compound, or a solvate of the compound or the salt, wherein the ring structure A in formula (2) is a ring selected from among azetidine, pyrrolidine, piperidine, piperazine, morpholine, homopiperazine, and oxazepane, and  $R^1$  represents 1 to 4 groups, which are identical to or different from one another, of halogeno groups or lower alkyl groups which have been substituted by a halogeno group.

14. A compound as described in any one of claims 1 to 10, a salt of the compound, or a solvate of the compound or the salt, wherein the group represented by formula (2) is a group selected from among a 3-dimethylaminoazetidin-1-yl

group, a 2,2-dimethyl-3-dimethylaminoazetidin-1-yl group, a 2-hydroxymethylazetidin-1-yl group, a 2-carbamoylazetidin-1-yl group, a 2-oxopyrrolidino group, a 2-hydroxymethylpyrrolidino group, a 2-carbamoylpyrrolidino group, a 2-fluoromethylpyrrolidino group, a 3-fluoropyrrolidino group, a 2-hydroxymethylpiperidino group, a 2-carbamoylpiperidino group, a 2-methylcarbamoylpiperidino group, a 2-dimethylcarbamoylpiperidino group, a 3-fluoropiperidino group, a 4-fluoropiperidino group, a 4,4-difluoropiperidino group, a 4-fluoromethylpiperidino group, a 4-methoxypiperidino group, a 3-oxo-4-methylpiperazino group, a 4-methylpiperazino group, a 4-ethylpiperazino group, a 4-isopropylpiperazino group, a 4-cyclopropylpiperazino group, a 2,4-dimethylpiperazino group, a 3,4-dimethylpiperazino group, a 3-cyclopropyl-4-methylpiperazino group, a 3,4,5-trimethylpiperazino group, a 2,2,4-trimethylpiperazino group, a 3,3,4-trimethylpiperazino group, a 2-cyclopropanespiro-4-methylpiperazino group, a morpholino group, a 3-carbamoylmorpholino group, a 1,1-dioxothiomorpholino group, a 3-oxo-4-methylhomopiperazino group, a 5-oxo-4-methylhomopiperazino group, a 4-methylhomopiperazino group, a 4-ethylhomopiperazino group, a 4-cyclopropylhomopiperazino group, and a 1,4-oxazepan-4-yl group.

15. A drug containing a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt.

16. A preventive and/or therapeutic agent for ischemic

diseases, containing a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt.

17. A platelet aggregation inhibitor containing a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt.

18. A pharmaceutical composition containing a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt, and a pharmacologically acceptable carrier therefor.

19. Use, for production of a drug, of a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt.

20. Use, for production of a preventive and/or therapeutic agent for ischemic diseases, of a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt.

21. Use, for production of a platelet aggregation inhibitor, of a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt.

22. A method for treating ischemic diseases comprising administering an effective amount of a compound as recited in any one of claims 1 to 14, a salt of the compound, or a solvate of the compound or the salt.